Public Employees Retirement System of Ohio Sells 2,903 Shares of DaVita Inc. $DVA

Public Employees Retirement System of Ohio decreased its holdings in shares of DaVita Inc. (NYSE:DVA) by 17.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,076 shares of the company’s stock after selling 2,903 shares during the period. Public Employees Retirement System of Ohio’s holdings in DaVita were worth $2,005,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. UMB Bank n.a. raised its position in DaVita by 65.5% during the 1st quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $29,000 after purchasing an additional 76 shares during the last quarter. National Pension Service raised its position in DaVita by 74.3% during the 1st quarter. National Pension Service now owns 197 shares of the company’s stock valued at $30,000 after purchasing an additional 84 shares during the last quarter. Y.D. More Investments Ltd bought a new position in DaVita during the 1st quarter valued at approximately $35,000. NewEdge Advisors LLC raised its position in shares of DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after acquiring an additional 88 shares in the last quarter. Finally, University of Texas Texas AM Investment Management Co. bought a new position in shares of DaVita in the 1st quarter worth approximately $83,000. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 0.5%

DVA stock opened at $132.17 on Friday. DaVita Inc. has a twelve month low of $126.07 and a twelve month high of $179.60. The firm has a market cap of $9.45 billion, a PE ratio of 13.00, a price-to-earnings-growth ratio of 0.95 and a beta of 1.13. The business has a 50 day moving average of $135.09 and a 200 day moving average of $140.22.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating analysts’ consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The company had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same quarter last year, the company earned $2.00 EPS. The firm’s revenue for the quarter was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In other DaVita news, insider James O. Hearty sold 2,351 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the sale, the insider directly owned 26,038 shares in the company, valued at approximately $3,905,700. This trade represents a 8.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

DVA has been the subject of several research reports. Truist Financial set a $148.00 target price on DaVita in a research report on Friday, August 8th. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Barclays decreased their target price on DaVita from $169.00 to $160.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. Finally, Bank of America decreased their target price on DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research report on Wednesday, September 10th. Three analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, DaVita has an average rating of “Reduce” and a consensus target price of $158.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.